870487-09-5

Basic information

• Product Name: Boc-Val-Cit-PABA
• Synonyms: Boc-Val-Cit-PABA;N-[(1,1-Dimethylethoxy)carbonyl]-L-valyl-N5-(aminocarbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide
• CAS NO: 870487-09-5
• Molecular Formula: C₂₃H₃₇N₅O₆
• Molecular Weight: 479.56978
• Product Categories: Linker;ADC LINKER
• Mol File: 870487-09-5.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 771.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.209±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.25±0.46(Predicted)
• CAS DataBase Reference: Boc-Val-Cit-PABA(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Val-Cit-PABA(870487-09-5)
• EPA Substance Registry System: Boc-Val-Cit-PABA(870487-09-5)

Safety Data

• Hazardous Substances Data: 870487-09-5(Hazardous Substances Data)

Usage

Description

Boc-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit peptide will specifically be cleaved by Cathepsin B. Boc group can be removed under acidic condition.

Upstream product

• 870487-04-0 (S)-(9H-fluoren-9-yl)methyl (1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate 
• 3392-12-9 Boc-Val-ONSu 
• 13734-41-3 t-Boc-L-valine 
• 1037794-22-1 (S)-2-amino-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide 
• 623-04-1 4-aminobenzenemethanol 
• 133174-15-9 (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanoic acid 
• 93964-78-4 methyl (S)-2-amino-5-ureidopentanoate hydrochloride 
• 372-75-8 Citrulline 
• 870487-08-4 (6S,9S)-1-amino-9-isopropyl-13,13-dimethyl-1,8,11-trioxo-12-oxa-2,7,10-triazatetradecane-6-carboxylic acid 

Downstream Products

• 870487-10-8 tert-butyl ((5)-3-methyl-1-(((5)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 
• 159857-79-1 (2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-N-[4-(hydroxymethyl)phenyl]-5-ureidopentanamide 

Relevant articles and documents

TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF A HEPATOCELLULAR RECEPTOR A2 PRODUCING ERYTHROPOIETIN (EPHA2)

The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

BICYCLE TOXIN CONJUGATES AND USES THEREOF

The present invention relates to Bicycle toxin conjugates, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof for preventing or treating a disease, disorder, or condition characterised by overexpression

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.